Lunit Inc. (KOSDAQ:328130)

South Korea flag South Korea · Delayed Price · Currency is KRW
38,800
-150 (-0.39%)
Aug 28, 2025, 3:30 PM KST
-0.39%
Market Cap1.13T
Revenue (ttm)73.89B
Net Income (ttm)-118.14B
Shares Out29.20M
EPS (ttm)-4,082.50
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume97,936
Average Volume170,745
Open39,000
Previous Close38,950
Day's Range38,450 - 39,300
52-Week Range35,450 - 85,800
Beta1.40
RSI32.07
Earnings DateAug 11, 2025

About Lunit

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such a... [Read more]

Industry Prepackaged Software
Founded 2013
Employees 298
Stock Exchange KOSDAQ
Ticker Symbol 328130
Full Company Profile

Financial Performance

In 2024, Lunit's revenue was 54.18 billion, an increase of 116.03% compared to the previous year's 25.08 billion. Losses were -82.42 billion, 124.0% more than in 2023.

Financial Statements

News

There is no news available yet.